Anand Mehra, MD
Anand joined Sofinnova Ventures in 2007 and is focused on working with entrepreneurs to build drug development companies that have the power to improve the lives of patients. He has led the firm’s investments in Vicept Therapeutics (Acquired: Allergan), Aerie Pharmaceuticals (NASDAQ: AERI), Aclaris (NASDAQ: ACRS), Prothena (NASDAQ: PRTA), Civitas (acquired by Acorda) and Spark Therapeutics (NASDAQ: ONCE), and he played an important role in the firm’s investment in SarCode (Acquired: Shire), Preglem (Acquired: Gedeon Richter), Amarin (NASDAQ: AMRN), and Nextwave Pharmacueticals (Acquired: Pfizer). He is currently a director of First Aid Shot Therapy, Marinus Pharmaceuticals, Merus and Spark Therapeutics.
Prior to joining Sofinnova Ventures, Anand worked at JP Morgan Partners in private equity and venture capital and was a consultant for McKinsey and Company advising pharma and biotech on core strategic issues. Anand received his MD from Columbia University’s College of Physicians and Surgeons and conducted NIH sponsored research on the outcomes, mechanism, and development of therapeutic agents for stroke. He graduated Phi Beta Kappa from the University of Virginia where he also spent three years as a firefighter at the Seminole Trail Fire Department in Charlottesville, Virginia – and he is an avid snowboarder.
Assistant: Jenn Symmons Email: firstname.lastname@example.org.